PDRN, made without animal-derived sources
The biology of PDRN
PDRN is DNA cut into short fragments, and every cell builds and mends its own DNA from the nucleotides those fragments supply. Published research links its effects to two routes, the nucleotide salvage pathway and the adenosine A2A receptor.
What changes when PDRN is produced without relying on animal-derived tissue? How does controlling the DNA fragments within a defined molecular-size range affect their consistency, biological activity, and therapeutic potential?
These are the kinds of questions our research is designed to answer, and to translate those findings into new medicines across five areas of human biology.
We expect what we find to change what a PDRN medicine can be.
A focus on building blocks the body already uses
Every cell relies on nucleotides to build and repair its DNA. Research suggests that as PDRN is broken down, its components can enter nucleotide salvage pathways. We are developing PDRN without animal-derived starting material, with tight control over the length of the DNA fragments we produce.
A narrower, defined range
Our target fragments are 20–80 base pairs, approximately 13–53 kilodaltons. PDRN described in the scientific literature commonly spans a much broader range.
From defined material to medicine
We control how our PDRN is made so that every batch is defined and consistent. We aim to carry that material from development toward medicines for patients.
Every number we keep travels with its date, its sample, its instrument and its operator.